alphavePPLPHARMA₹211.99

Piramal Pharma Ltd.

₹ CrorePeersDIVISLAB SYNGENE GLAND WOCKPHARMA ASTERDM COHANCE LALPATHLAB NATCOPHARMMcap ₹28,134 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Non-current Assets
+ Property, Plant & Equipment	3,872.6	4,176.0	4,450.7	4,450.7
+ Capital Work-in-Progress	565.7	489.1	799.2	799.2
+ Goodwill	1,122.6	1,148.2	1,257.4	1,257.4
+ Other Intangibles	2,617.1	2,450.9	2,583.9	2,583.9
+ Intangibles under Development	550.1	487.8	300.6	300.6
+ Investments (Equity Method)	205.3	226.8	244.2	244.2
+ Non-current Investments	34.9	44.3	60.8	60.8
+ Other Non-current Financial Assets	20.8	20.7	40.3	40.3
Non-current Financial Assets	55.8	65.0	101.1	101.1
+ Deferred Tax Assets	386.5	393.1	514.7	514.7
+ Other Non-current Assets	471.7	443.7	521.5	521.5
Total Non-current Assets	9,847.3	9,880.6	10,773.4	10,773.4
Current Assets
+ Inventories	2,175.9	2,312.7	3,064.4	3,064.4
+ Current Investments	144.7	19.6	131.8	131.8
+ Trade Receivables	2,134.4	2,349.5	2,157.7	2,157.7
+ Cash & Cash Equivalents	356.8	369.0	1,199.9	1,199.9
+ Other Bank Balances	125.7	132.5	23.8	23.8
+ Other Current Financial Assets	15.9	55.6	65.5	65.5
Current Financial Assets	2,777.6	2,926.1	3,578.6	3,578.6
+ Other Current Assets	511.0	551.8	548.7	548.7
Total Current Assets	5,464.5	5,797.0	7,191.7	7,191.7
Total Assets	15,311.8	15,677.6	17,965.0	17,965.0
Equity
+ Equity Share Capital	1,323.0	1,324.4	1,327.2	1,327.2
+ Other Equity / Reserves	6,588.4	6,801.1	6,835.5	6,835.5
Equity — Owners of Parent	7,911.4	8,125.5	8,162.6	8,162.6
Total Equity	7,911.4	8,125.5	8,162.6	8,162.6
Liabilities
+ Borrowings — Non-current	2,483.8	3,214.1	4,300.0	4,300.0
+ Other Non-current Financial Liab	118.0	99.2	135.4	135.4
Non-current Financial Liabilities	2,601.7	3,313.2	4,435.4	4,435.4
+ Provisions — Non-current	32.3	48.7	94.3	94.3
+ Deferred Tax Liabilities	229.2	248.4	358.2	358.2
+ Other Non-current Liabilities	167.9	175.6	156.3	156.3
Non-current Liabilities	3,031.1	3,785.9	5,044.1	5,044.1
+ Borrowings — Current	2,075.1	1,506.2	1,195.5	1,195.5
+ Trade Payables	1,538.4	1,533.8	2,479.1	2,479.1
+ Other Current Financial Liab	284.6	400.0	437.7	437.7
Current Financial Liabilities	3,898.1	3,439.9	4,112.3	4,112.3
+ Provisions — Current	43.6	42.9	42.2	42.2
+ Current Tax Liabilities	40.3	9.6	10.6	10.6
+ Other Current Liabilities	387.4	273.9	593.2	593.2
Current Liabilities	4,369.3	3,766.3	4,758.3	4,758.3
Total Liabilities	7,400.4	7,552.1	9,802.4	9,802.4
Total Equity & Liabilities	15,311.8	15,677.6	17,965.0	17,965.0
Assets — additional as-filed lines
+ Current Tax Assets	—	6.4	0.0	0.0
Trade Payables — MSME split
+ Dues to Micro & Small — Current	—	42.0	101.6	101.6
+ Dues to Other Creditors — Current	—	1,491.8	2,377.5	2,377.5

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.